These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 34637846)
1. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Jain S; Venkataraman A; Wechsler ME; Peppas NA Adv Drug Deliv Rev; 2021 Dec; 179():114000. PubMed ID: 34637846 [TBL] [Abstract][Full Text] [Related]
2. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
4. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328 [TBL] [Abstract][Full Text] [Related]
6. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. Suzuki Y; Ishihara H Drug Metab Pharmacokinet; 2021 Dec; 41():100424. PubMed ID: 34757287 [TBL] [Abstract][Full Text] [Related]
7. From mRNA sensing to vaccines. Fauci AS; Merad M; Swaminathan S; Hur S; Topol E; Fitzgerald K; Reis e Sousa C; Corbett KS; Bauer S Immunity; 2021 Dec; 54(12):2676-2680. PubMed ID: 34739870 [TBL] [Abstract][Full Text] [Related]
8. [Vaccine development based on RNA technology platforms]. Guo X; Li J; Wang HM; Qiu J; Li Z; Huang F; Li J; Sun XD Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Aug; 58(8):1263-1277. PubMed ID: 39142899 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519 [TBL] [Abstract][Full Text] [Related]
10. Comparative Profiles of SARS-CoV-2 Spike-Specific Human Milk Antibodies Elicited by mRNA- and Adenovirus-Based COVID-19 Vaccines. Yang X; Fox A; DeCarlo C; Norris C; Griffin S; Wedekind S; Flanagan JM; Shenker N; Powell RL Breastfeed Med; 2022 Aug; 17(8):638-646. PubMed ID: 35675683 [No Abstract] [Full Text] [Related]
11. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD; Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053 [TBL] [Abstract][Full Text] [Related]
12. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. Esquivel-Valerio JA; Skinner-Taylor CM; Moreno-Arquieta IA; Cardenas-de la Garza JA; Garcia-Arellano G; Gonzalez-Garcia PL; Almaraz-Juarez FDR; Galarza-Delgado DA Rheumatol Int; 2021 Dec; 41(12):2105-2108. PubMed ID: 34622311 [TBL] [Abstract][Full Text] [Related]
13. Toward Achieving a Vaccine-Derived Herd Immunity Threshold for COVID-19 in the U.S. Gumel AB; Iboi EA; Ngonghala CN; Ngwa GA Front Public Health; 2021; 9():709369. PubMed ID: 34368071 [TBL] [Abstract][Full Text] [Related]
14. Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]. Jawalagatti V; Kirthika P; Lee JH Front Immunol; 2022; 13():884862. PubMed ID: 35592330 [TBL] [Abstract][Full Text] [Related]
15. Time and cost of administering COVID-19 mRNA vaccines in the United States. Yarnoff B; Bodhaine S; Cohen E; Buck PO Hum Vaccin Immunother; 2021 Nov; 17(11):3871-3875. PubMed ID: 34613860 [TBL] [Abstract][Full Text] [Related]
16. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related]
17. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US. Hause AM; Zhang B; Yue X; Marquez P; Myers TR; Parker C; Gee J; Su J; Shimabukuro TT; Shay DK JAMA Netw Open; 2022 Jul; 5(7):e2222241. PubMed ID: 35838667 [TBL] [Abstract][Full Text] [Related]
18. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
19. mRNA-based vaccines - global approach, challenges, and could be a promising wayout for future pandemics. Makhijani S; Elossaily GM; Rojekar S; Ingle RG Pharm Dev Technol; 2024 Jul; 29(6):559-565. PubMed ID: 38814266 [TBL] [Abstract][Full Text] [Related]
20. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection. Costanzo M; De Giglio MAR; Roviello GN Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]